ArticleFrontiers in genetics2026
Exploring Ebola virus-associated gene expression through comparative analysis.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ebola virus (EBOV) infection triggers intense host transcriptional responses that overlap extensively with those induced by other viral and bacterial pathogens. This overlap complicates the identification of EBOV-specific gene expression signatures and limits diagnostic specificity. Defining transcriptional markers that distinguish EBOV from other infections is essential for improving molecular diagnostics and advancing understanding of EBOV-specific host responses. Methods: We developed a multi-step filtering framework using blood-derived RNA-Seq data from nonhuman primates and human cohorts organized into independent training and test sets. In the training cohort, differential expression analysis was performed using an edgeR-based GLMQL-MAS approach to identify EBOV-associated genes. Candidates were filtered against non-EBOV comparator datasets, including mpox virus, influenza, bacterial pneumonia, acute HIV-1 infection, and multiple SARS-CoV-2 variants, to remove broadly shared host-response genes. Genes included in the NanoString nCounter® Host Response Panel were additionally excluded. The resulting EBOV-specific signature was evaluated in independent EBOV and non-EBOV test cohorts using principal component analysis and logistic regression. Functional enrichment was assessed using KEGG pathways. Results: Initial analysis identified numerous interferon-stimulated genes that were similarly upregulated across infections. After cross-infection filtering and NanoString exclusion, 281 EBOV-specific genes were identified. Optimization within the training cohort yielded a top-50 gene set that clearly separated EBOV from Non-EBOV samples. In the independent test cohort, classification performance improved substantially, with the F1 score increasing from 37.5% when all genes were used to 95.0% after applying the top-50 gene set. Enrichment analysis of the top-50 EBOV-specific genes revealed significant association with vascular, coagulation, secretory, and metabolic pathways. Discussion: Structured cross-pathogen filtering enables identification of EBOV-specific transcriptional features beyond shared antiviral responses. The validated gene signature generalizes across independent cohorts and highlights biologically distinct pathways, which supports its potential utility for host-based diagnostic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.